Literature DB >> 22940833

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

S Goldman, L Smith, J R Anderson, S Perkins, L Harrison, M B Geyer, T G Gross, H Weinstein, S Bergeron, B Shiramizu, W Sanger, M Barth, J Zhi, M S Cairo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22940833      PMCID： PMC4539148          DOI： 10.1038/leu.2012.255

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.

Authors:  Bruce Shiramizu; Stanton Goldman; Ian Kusao; Melissa Agsalda; James Lynch; Lynette Smith; Lauren Harrison; Erin Morris; Thomas G Gross; Warren Sanger; Sherrie Perkins; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2011-04-18       Impact factor: 6.998

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.

Authors:  Mitchell S Cairo; Richard Sposto; Mary Gerrard; Anne Auperin; Stanton C Goldman; Lauren Harrison; Ross Pinkerton; Martine Raphael; Keith McCarthy; Sherrie L Perkins; Catherine Patte
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

5.  Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults.

Authors:  S B Murphy
Journal:  Semin Oncol       Date:  1980-09       Impact factor: 4.929

6.  Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

Authors:  Mitchell S Cairo; Mary Gerrard; Richard Sposto; Anne Auperin; C Ross Pinkerton; Jean Michon; Claire Weston; Sherrie L Perkins; Martine Raphael; Keith McCarthy; Catherine Patte
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

8.  A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Timothy C Griffin; Sheila Weitzman; Howard Weinstein; Myron Chang; Mitchell Cairo; Robert Hutchison; Bruce Shiramizu; Joseph Wiley; Deborah Woods; Margaret Barnich; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

9.  The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.

Authors:  Yi-Fu He; Yu-Hong Li; Feng-Hua Wang; Wen-Qi Jiang; Rui-Hua Xu; Xiao-Fei Sun; Zhong-Jun Xia; Hui-Qiang Huang; Tong-Yu Lin; Li Zhang; Shi-Ping Bao; You-Jian He; Zhong-Zhen Guan
Journal:  Ann Hematol       Date:  2008-02-26       Impact factor: 3.673

10.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113
View more
  49 in total

1.  Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.

Authors:  Matthew J Barth; Stanton Goldman; Lynette Smith; Sherrie Perkins; Bruce Shiramizu; Thomas G Gross; Lauren Harrison; Warren Sanger; Mark B Geyer; Lisa Giulino-Roth; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2013-06-27       Impact factor: 6.998

Review 2.  Non-Hodgkin Lymphoma in Children.

Authors:  John T Sandlund
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 3.  Pediatric lymphomas and histiocytic disorders of childhood.

Authors:  Carl E Allen; Kara M Kelly; Catherine M Bollard
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

4.  Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.

Authors:  Sanghoon Lee; Nancy S Day; Rodney R Miles; Sherrie L Perkins; Megan S Lim; Janet Ayello; Carmella van de Ven; Lauren Harrison; Nader K El-Mallawany; Stanton Goldman; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2017-05-04       Impact factor: 6.998

5.  Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis.

Authors:  Kari L Bjornard; Vasiliki Leventaki; Kim E Nichols; John T Sandlund; Susan Prockop; Matthew J Ehrhardt
Journal:  Pediatr Blood Cancer       Date:  2018-08-27       Impact factor: 3.167

6.  Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.

Authors:  Stanton Goldman; Lynette Smith; Paul Galardy; Sherrie L Perkins; John Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Bruce Shiramizu; Matthew Barth; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

Review 7.  Pharmacotherapeutic Management of Pediatric Lymphoma.

Authors:  Christine Mauz-Körholz; Natascha Ströter; Julia Baumann; Ante Botzen; Katharina Körholz; Dieter Körholz
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

8.  Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

Authors:  Bruce Shiramizu; Stanton Goldman; Lynette Smith; Melissa Agsalda-Garcia; Paul Galardy; Sherrie L Perkins; J Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Matthew J Barth; Lara Mussolin; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2015-04-08       Impact factor: 6.998

9.  Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.

Authors:  Yaya Chu; Ashlin Yahr; Brian Huang; Janet Ayello; Matthew Barth; Mitchell S Cairo
Journal:  Oncoimmunology       Date:  2017-06-20       Impact factor: 8.110

Review 10.  Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.

Authors:  Catherine M Bollard; Megan S Lim; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.